SHORT COMMUNICATION

SARS-CoV-2 infection in persons living with HIV: A single center prospective cohort

Franco Maggiolo1,2 | Fabio Zoboli1 | Marco Arosio3,4 | Daniela Valenti2,5 | Davide Guarneri3,4 | Lorena Sangiorgio3,4 | Diego Ripamonti1 | Annapaola Callegaro3

1Department of Medicine, Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy
2Department of Medicine, Unit of HIV related diseases and experimental therapies, ASST Papa Giovanni XXIII, Bergamo, Italy
3Department of Laboratory, Biobanking Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
4Department of Laboratory, Microbiology and Virology Laboratory, ASST Papa Giovanni XXIII, Bergamo, Italy
5FROM Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy

Correspondence
Franco Maggiolo, ASST Papa Giovanni XXIII, Bergamo 28127, Italy.
Email: franco31556@hotmail.com

Abstract
Information about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in HIV-infected individuals is scarce. In this prospective study, we included HIV (human immunodefeciency virus)-infected individuals (people living with HIV [PLWHIV]) with confirmed SARS-CoV-2 infection and compared them with PLWHIV negative for SARS-CoV-2. We compared 55 cases of SARS-CoV-2 infection with 69 asymptomatic PLWHIV negative for SARS-CoV-2 reverse transcription-polymerase chain reaction and/or serology. There was no significant difference between SARS-CoV-2 positive or negative patients for age distribution, gender, time with HIV infection, nadir CD4+ cell counts, type and number of co-morbidities, current CD4 and CD8 counts and type of anti-HIV therapy. Positive patients presented with a median of three symptoms (interquartile range, 1-3). Most common symptoms were fever (76%), dyspnea (35%), anosmia (29%) non-productive cough (27%), fatigue (22%), and ageusia (20%). Ten patients (18%) were completely asymptomatic. Four (7.2%) subjects died of coronavirus disease 2019. Factors significantly (P < .05) associated with death included age and number of co-morbidities, while time from HIV infection and lower current CD4 counts were significant only in univariate analysis. HIV-infected individuals are not protected from SARS-CoV-2 infection or have a lower risk of severe disease. Indeed, those with low CD4 cell counts might have worse outcomes. Infection is asymptomatic in a large proportion of subjects and this is relevant for epidemiological studies.

KEYWORDS
asymptomatic, CD4, CNS, cohort, co-morbidities, COVID-19, HIV, mortality, risk factors, SARS-CoV-2, symptoms

1 | INTRODUCTION

On 31 December 2019 an outbreak of pneumonia was first reported in Wuhan, China, and soon after identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the disease due to this infection was named coronavirus disease 2019 (COVID-19). The increasing number of cases of COVID-19 worldwide, induced World Health Organization to declare a pandemic. Italy is one of the most affected Countries in Europe with 238,499 confirmed cases as of 21 June 2020. The Province of Bergamo with about 1,100,000 inhabitants and 14,120 infected subjects is one of the focal areas of the Italian epidemic. Very little is known about how persons living with human immunodeficiency virus (PLWHIV) could react to SARS-CoV-2 infection. It has been postulated that human immunodeficiency virus (HIV)-infected individuals might be at an increased risk because...
of the presence of comorbidities, lower CD4 cell counts, or unsuppressed virus.\textsuperscript{4-6} Conversely, it has been suggested that immunosuppression might prevent or lower the severe cytokine storm observed in COVID-19 reducing its severity.\textsuperscript{7,8} Finally, antiretrovirals have been indicated as able to modify the risk of infection with SARS-CoV-2 and its clinical picture in PLWHIV.\textsuperscript{8,9}

This uncertainty is due to the paucity of work on the topic, being available data based on small cases series,\textsuperscript{4,10-14} or on two larger cohorts either uncontrolled\textsuperscript{15} or with controls untested for SARS-CoV-2.\textsuperscript{5}

This is the first cohort study in which PLWHIV either symptomatic or not were tested for SARS-CoV-2.

2 | METHODS

2.1 | Study characteristics

This is a cohort, single center, clinical, prospective study performed in a Province of Northern Italy highly hit by the SARS-CoV-2 epidemic. Aim of the study was to identify possible characteristics of PLWHIV that could correlate with the risk of acquiring SARS-CoV-2 infection and, in the case of infection, would influence the outcome.

2.2 | Data collection

Since the beginning of the epidemic, data of all suspected or confirmed COVID-19 cases were recorded in a specific database linked to a common research project authorized by the local Ethical Committee. All patients gave their informed consent. Data for the present cohort study were extracted from this database. They were cross-linked with information from the outpatient clinic electronic health records. Data of patients not admitted to the hospital were obtained by each patient during a visit performed in the first 15 days of June. All these patients subscribed an informed consent, too.

Recorded variables were age, gender, comorbidities, HIV-specific variables, such as year of HIV infection diagnosis, nadir and most recent (eg, within 3 months from 1st March 2020) CD4 cell counts, CD8 cell counts, CD4/CD8 ratios, HIV-RNA plasma levels, current antiretroviral therapy. Clinical characteristics of COVID-19, and outcomes were recorded for SARS-CoV-2 positive patients.

2.3 | Laboratory procedures

During the acute phase of the epidemics, Laboratory diagnosis of SARS-CoV-2 infection was done by reverse transcription-polymerase chain reaction (RT-PCR) with primer and probes targeting E, RdRp and N genes. Nasopharyngeal swabs or lower respiratory tract aspirates were tested only in individuals admitted to the hospital as public health authorities’ regulations did not recommend tests in individuals with mild symptoms not admitted to hospitals. Later on, for specific categories (eg, health-care workers) nasopharyngeal swabs were permitted. In all other cases, the diagnosis was achieved by means of serological tests.

Serological diagnosis was made with VivaDiagTM COVID-19 immunoglobulin M/immunoglobulin G immune-chromatographic assay from VivaChekTM Biotech (China), performed according to manufacturer’s instructions.

Blood tests were done according to the clinical needs of each patient by means of routine laboratory procedures. Radiologists performed Chest x-ray assessments.

2.4 | Definitions

Confirmed COVID-19 was defined by positive RT-PCR for SARS-CoV-2 in respiratory samples or a positive serological test. Suspected cases were those in individuals with clinical and pathological findings compatible with COVID-19, but whose RT-PCR results were inconclusive in the absence of any other proven cause (eg, Pneumocystis jiroveci pneumonia).

The severity of disease was scored based on the worse type of respiratory support needed (eg, invasive mechanical ventilation, noninvasive mechanical ventilation, oxygen mask).

Confirmed SARS-CoV-2 negative patients were asymptomatic, with either RT-PCR or serology or both tests negative.

2.5 | Statistical analysis

No sample size was calculated given that all known individuals with a diagnosis of COVID-19 were included. Continuous variables are presented as median and interquartile range (IQR). Categorical variables are expressed as number of patients (percentage).

Comparisons were assessed by using the Mann-Whitney U test for continuous variables, whereas categorical variables were assessed by the $\chi^2$ test. We used a binary logistic regression model to explore the factors associated with COVID-19 diagnosis and the risk of death. Statistical significance was defined as a two-sided $P < .05$. All statistics were done with SPSS Statistics for Windows, version 17.0.

2.6 | Role of the funding source

This study has no funder.

3 | RESULTS

At our center, 2898 PLWHIV are currently in active follow-up. Among these, we identified 55 cases of SARS-CoV-2 infection either by RT-PCR test (16 cases, 29%), serology (33 cases, 60%), or clinical grounds (6 cases, 11%) when tests were negative, the clinical picture was highly suggestive and no other explanation was found. We
compared these cases with 69 PLWHIV who tested negative for RT-PCR (16 cases, 23%) or serology (53 cases, 77%). Baseline characteristics are reported in Table 1. No significant difference was observed between SARS-CoV-2 positive and negative patients for age distribution, gender, time with HIV infection, nadir CD4 cell counts, type and number of co-morbidities, current CD4 and CD8 counts and type of anti-HIV therapy. The only exception was a barely significant difference in the use of integrase inhibitors (higher in in SARS-CoV-2 tinfected), while other anchor drugs and backbone components were used in similar proportions. Specifically, as the role of tenofovir is debated, we compared subjects receiving or not this drug. Tenofovir was a part of the antiretroviral regimen in 33 (60.0%) of SARS-CoV-2 positive subjects and in 42 (60.8%) of controls. In the positive group, only one patient had detectable HIV-RNA.

### TABLE 1 baseline characteristics in 55 subjects SARS-CoV-2 positive and 69 SARS-CoV-2 negative

| Variable                        | SARS-CoV-2 positive | SARS-CoV-2 negative | Total    | P value |
|---------------------------------|---------------------|---------------------|----------|---------|
| Gender                          |                     |                     |          | .401    |
| Male                            | 44 (80.0%)          | 50 (72.5%)          | 94 (75.8%)|         |
| Female                          | 11 (20.0%)          | 19 (27.5%)          | 30 (24.2%)|         |
| Age, y                          | 54 (49-58)          | 52 (46-59)          | 51 (46-59) | .249    |
| Risk factor for HIV             |                     |                     |          | .434    |
| Heterosexual contacts           | 24 (43.7%)          | 38 (55.0%)          | 62 (50.0%)|         |
| MSM                             | 18 (32.7%)          | 17 (24.7%)          | 35 (28.2%)|         |
| IVDU                            | 13 (23.6%)          | 14 (20.3%)          | 27 (21.8%)|         |
| Years since HIV infection       | 16 (9-23)           | 14 (9-23)           | 13 (8-18) | .757    |
| Nadir CD4 count, cells per µL   | 281 (37-550)        | 292 (88-528)        | 292 (37-547) | .788 |
| Antiretroviral drugs            |                     |                     |          |         |
| NRTIs                           | 47 (85.4%)          | 56 (81.1%)          | 103 (83.0%)| .633    |
| NNRTIs                          | 20 (36.4%)          | 31 (44.9%)          | 51 (41.1%) | .363    |
| PIs                             | 11 (20.0%)          | 24 (34.7%)          | 35 (28.2%) | .075    |
| INIs                            | 32 (58.2%)          | 27 (39.1%)          | 59 (47.6%) | .046    |
| Number of ARV drugs             | 3 (2-3)             | 3 (3-3)             | 3 (2-3)  | .422    |
| Number of co-morbidities        | 1 (0-1)             | 1 (0-1)             | 1 (0-1)  | .642    |
| Major co-morbidities            |                     |                     |          |         |
| Cardiovascular diseases         | 9 (16.4%)           | 5 (7.2%)            | 14 (11.2%)| .154    |
| Hypertension                    | 12 (21.8%)          | 11 (15.9%)          | 23 (18.5%)| .487    |
| Gastro-enteric                  | 6 (10.9%)           | 6 (8.7%)            | 12 (9.6%) | .764    |
| Malignancies                    | 5 (9.0%)            | 8 (11.6%)           | 13 (10.4%)| .772    |
| Neurological                    | 4 (7.3%)            | 9 (13.0%)           | 13 (10.4%)| .383    |
| Diabetes                        | 3 (5.5%)            | 3 (4.3%)            | 6 (4.8%)  | 1.000   |
| HBV co-infection                | 5 (9.0%)            | 5 (7.2%)            | 10 (8.0%) | .749    |
| HCV co-infection                |                     |                     |          | .985    |
| Negative                        | 41 (74.5%)          | 52 (75.3%)          | 93 (75.0%)|         |
| Cured                           | 13 (23.6%)          | 16 (23.1%)          | 29 (23.4%)|         |
| HCV-RNA positive                | 1 (1.8%)            | 1 (1.4%)            | 2 (1.6%)  |         |
| Last CD4 count, cells per µL    | 904 (557-1110)      | 822 (556-1035)      | 829 (559-1054) | .486 |
| Last CD8 count, cells per µL    | 953 (633-1279)      | 911 (591-1226)      | 921 (629-1262) | .720    |
| Last CD4/CD8 ratio              | 0.89 (0.64-1.20)    | 0.92 (0.56-1.20)    | 0.96 (0.54-1.2) | .731    |
| Last HIV-RNA < 50 copies/mL     | 54 (98.1%)          | 64 (92.7%)          | 118 (95.2%)| .376    |

Note: Number and (percentages) or median and (IQR).
Abbreviations: ARV, antiretroviral; HIV, human immunodeficiency virus; INI, integrase inhibitor; IQR, interquartile range; IVDU, intravenous drug users; MSM, men who have sex with men; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
In our casuistry, the seriousness of the infection was not influenced by the current immunological situation nor by the previous immune depressive status as measured by the nadir CD4 cell counts. As a matter of fact, patients with a fatal outcome presented with lower CD4 counts, even if the difference was not statistically significant when analyzed according to a multivariable model. These findings confirm previously reported observations.6,15

Most previous studies in PLWHIV concentrated on patients admitted to the hospital because of COVID-19.6,8,15 In our cohort, most of the included patients were not admitted to the hospital, testifying that, even in HIV-positive subjects, SARS-CoV-2 may present as a mild diseases not requiring hospitalization.

4 | DISCUSSION

Our study addresses some of the unknown aspects of SARS-CoV-2 infection in PLWHIV.

A distinctive aspect of our study is the fact that all included patients were tested for SARS-CoV-2 making it one of the largest cohort of individuals with HIV and demonstrated SARS-CoV-2 co-infection.

Interestingly, none of the classical variables linked to HIV infection, such as nadir CD4 cell counts, time of HIV infection or current CD4 counts were predictive of the risk of acquiring SARS-CoV-2 infection, nor the use of specific antiretrovirals resulted having a protective effect as previously reported.8,9

It can be postulated that in PLWHIV, as in the general population, other variables not HIV-related, such as work activities or adherence to lock-down and social-distancing procedures might be prominent in determining the risk of infection.13

Previous studies have suggest that immunosuppression and low CD4 cell counts might protect HIV-infected individuals from developing the cytokine storm observed in patients with COVID-19.7,8,14

In our casuistry, the seriousness of the infection was not influenced by the current immunological situation nor by the previous immune depressive status as measured by the nadir CD4 cell counts. As a matter of fact, patients with a fatal outcome presented with lower CD4 counts, even if the difference was not statistically significant when analyzed according to a multivariable model. These findings confirm previously reported observations.6,15

Most previous studies in PLWHIV concentrated on patients admitted to the hospital because of COVID-19.6,8,15 In our cohort, most of the included patients were not admitted to the hospital, testifying that, even in HIV-positive subjects, SARS-CoV-2 may present as a mild diseases not requiring hospitalization.

| Variable                        | Survivors | Deceased | P value Univariate | P value Multivariate |
|---------------------------------|-----------|----------|--------------------|---------------------|
| Age, y                          | 54 (48-58)| 65 (59-69)| .025               | .044                |
| Years since HIV infection       | 14 (9-23 )| 24 (20-32)| .044               | .053                |
| Number of co-morbidities        | .037      | .029     |                    |                     |
| None                            | 27 (100%) | 0        |                    |                     |
| One                             | 15 (93%)  | 1 (7%)   |                    |                     |
| Two                             | 5 (83%)   | 1 (17%)  |                    |                     |
| More than two                   | 4 (66%)   | 2 (44%)  |                    |                     |
| Last CD4 count, cells per µL    | 913 (557-1119) | 514 (427-601) | .001 | .187 |

Note: Number and (percentages) or median and (IQR).

Abbreviations: COVID-19, coronavirus disease 2019; HIV, human immunodeficiency virus; IQR, interquartile range.
hospital admission or intensive care.\textsuperscript{16,17} As a matter of fact, the proportion of asymptomatic patients resulted quite high (18%). Such a value counting for almost a fifth of the potentially infected subjects needs to be taken into account in future analysis of the incidence of SARS-CoV-2 in HIV infected subjects\textsuperscript{17} and potentially strengthens the use of serological tests that allowed us to detect subjects with mild symptoms or even without any symptom.

Our study has several limitations. First, the small number of individuals prevents us from generalizing our results, also because obtained in a highly epidemic area and therefore not necessarily applicable in places with a different prevalence. Second, the small sample does not allow us to definitively establish the role of immune status or the presence of comorbidities in the clinical presentation and outcomes. Third, as stated, some bias may exist in the rate of infection because local recommendations restricted confirmatory testing. Although we included all the HIV-infected individuals with documented SARS-CoV-2 infection, the high rate of asymptomatic patients we found raises the doubt that more unknown subjects could have been infected.

The two specific cases we report in the results stress the risk of misdiagnosis, especially at the beginning of the epidemic and the importance of extended testing even if in extremely immune-depressed patients the immunological response may fail to mount.

In conclusion, none of the parameters classically used to define immune suppression or risk of immune impairment in HIV-positive subjects does correlate with the risk of acquiring SARS-CoV-2 infection. Although low CD4 counts were not associated with the positivity for SARS-CoV-2, relative immunosuppression did seem to affect disease severity, and it might be associated with adverse outcomes. By contrast, there was no evidence that any specific antiretroviral drug affected SARS-CoV-2 infection or COVID-19 severity.

The disease may cover a vast range of clinical pictures, being almost one fifth of infected individuals asymptomatic.

Variables already described for the general population as risk factors for a more severe disease, such as advanced age and the presence of multiple co-morbidities do apply to PLWHIV, too.

ACKNOWLEDGMENT
FM received research grants from Gilead, ViiV, Janssen and acted as member of advisory board for Gilead, ViiV, Janssen and Merck.

CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.

DATA AVAILABILITY STATEMENT
Data available on request from the authors.

ORCID
Franco Maggiolo  http://orcid.org/0000-0002-9791-0072

REFERENCES
1. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020;323:709.
2. WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. Geneva: World Health Organization. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020. Accessed June 21, 2020.
3. Italian Ministry of Health (Ministero della Salute). Novel coronavirus. http://www.salute.gov.it/portale/nuovocoronavirus/homeNuovoCoronavirus.jsp?lingua=english. Accessed June 21, 2020.
4. Zhu F, Cao Y, Xu S, Zhou M. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China. J Med Virol. 2020;92:529-530. https://doi.org/10.1002/jmv.25732
5. Zhu F, Cao Y, Xu S, Zhou M. Reply to comments on “Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China. J Med Virol. 2020. https://doi.org/10.1002/jmv.25838
6. Vizcarra P, Pérez-Elias MJ, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020. https://doi.org/10.1016/S2352-3018(20)30161-3
7. Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV/AIDS Rep. 2017;14:93-100.
8. Gervasoni C, Meraviglia P, Riva A, et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa579
9. Jockusch S, Tao C, Li X, et al. Triphosphates of the two components in DESCOVY and TRUVADA are inhibitors of the SARS-CoV-2 polymerase. bioRxiv. 2020. https://doi.org/10.1101/2020.04.03.229393
10. Blanco JL, Ambrosioni J, García F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7:314. https://doi.org/10.1016/S2352-3018(20)30111-9
11. Ridgway JP, Farley B, Benoit J-L, et al. A case series of five people living with HIV hospitalized with COVID-19 in Chicago, Illinois. AIDS Patient Care STDs. 2020. https://doi.org/10.1089/apc.2020.0103
12. Zhao J, Liao X, Wang H, et al. Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa408
13. Chou R, Dana T, Buckley DI, Selph S, Fu R, Totten AM. Epidemiology of and risk factors for coronavirus infection in health care workers. Ann Intern Med. 2020;173:120-136. https://doi.org/10.7326/M20-1632
14. Marimuthu J, Kumar BS, Aravind Gandhi P. HIV and SARS-CoV-2 co-infection: a retrospective, record based, case series from South India. J Med Virol. 2020. https://doi.org/10.1002/jmv.26271
15. Ruan L, Zhang Y, Luo Y, et al. Clinical features and outcomes of four HIV patients with COVID-19 in Wuhan, China. J Med Virol. 2020. https://doi.org/10.1002/jmv.26223
16. Masukume G, Mapanga W, Grinberg S, van Zyl DS. COVID-19 and HIV co-infection an emerging consensus. J Med Virol. 2020. https://doi.org/10.1002/jmv.26370
17. Patel RH. Clinical outcomes and prognosis of patients with HIV and SARS-CoV-2 coinfection. J Med Virol. 2020. https://doi.org/10.1002/jmv.26177

How to cite this article: Maggiolo F, Zoboli F, Arosio M, et al. SARS-CoV-2 infection in persons living with HIV: A single center prospective cohort. J Med Virol. 2021;93:1145-1149. https://doi.org/10.1002/jmv.26352